Biotech
Thursday, May 23rd, 2024 6:10 pm EDT
Key Points
- Big pharmaceutical companies are heavily investing in targeted radiopharmaceutical therapy, viewing it as a significant opportunity in cancer treatment. This therapy delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule.
- RBC Capital Markets estimates a $25 billion market opportunity for targeted radiopharmaceutical therapy, highlighting its early-stage development and potential for value creation. Recent acquisitions in this field, including Novartis’ purchase of Mariana Oncology for $1 billion, demonstrate growing interest and aggressive strategies among pharmaceutical giants.
- Competitors like Eli Lilly and Bristol-Myers Squibb have also made significant acquisitions in radiopharmaceutical companies, indicating a competitive race in this emerging field. The potential of targeted radiotherapies extends beyond prostate cancer, with applications in various cancer types, offering a vast opportunity for growth and innovation in cancer treatment.
Big pharmaceutical companies are investing heavily in targeted radiopharmaceutical therapy, considering it a significant opportunity in cancer treatment. This therapy delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. Analysts at RBC Capital Markets estimate a market opportunity of $25 billion for this space, emphasizing its early-stage development and potential for value creation. Recent acquisitions in this field, such as Novartis’ purchase of Mariana Oncology for $1 billion, reflect a growing interest. Novartis already has two targeted radiotherapies on the market, with Pluvicto nearing blockbuster status and expected to generate substantial revenue by 2028. Other pharmaceutical giants like Eli Lilly and Bristol-Myers Squibb have also joined the trend, making significant acquisitions in radiopharmaceutical companies. The focus on targeted radiotherapies extends beyond prostate cancer, with potential applications in breast, lung, and other cancers. Companies are exploring combinations with other treatments like immunotherapy and leveraging decades of cancer research to identify new opportunities. Analysts see a vast potential for targeted radiotherapies, considering the breadth of cancer research and targeting possibilities available.
For the full original article on CNBC, please click here: https://www.cnbc.com/2024/05/23/this-up-and-coming-cancer-treatment-could-be-a-25-billion-market-opportunity.html
